451
Participants
Start Date
June 2, 2015
Primary Completion Date
August 12, 2020
Study Completion Date
August 12, 2020
BGB-A317
In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.
BGB-A317
Participants were assigned to different groups based on their tumor types
National Cheng Kung University Hospital, Tainan City
Auckland City Hospital, Grafton
Chris O'Brien Lifehouse, Camperdown
Nucleus Network, Melbourne
Seoul National University Hospital, Seoul
Cabrini Hospital, Malvern
Waikato, Hamilton
Princess Alexandra Hospital, Woolloongabba
Tasman Oncology Research Ltd, Southport
Asan Medical Center, Seoul
Wellington Hospital, Wellington
Taipei Veterans General Hospital, Taipei
Seoul National University Bundang Hospital, Seongnam
Linkou Chang Gung Memorial Hospital, Taoyuan District
Chang Gung Memorial Hospital, Sachin, Taoyuan District
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
Massachusetts General Hospital, Boston
Oncology Consultants, P.A., Houston
Prince of Wales Hospital, Sydney
Royal Adelaide Hospital, Adelaide
The Queen Elizabeth Hospital, Woodville South
Monash Health, Clayton
Peter MacCallum Cancer Centre, East Melbourne
Austin Health Hospital, Heidelberg
Royal Melbourne Hospital, Melbourne
Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands
National Taiwan University Hospital, Taipei
Lead Sponsor
BeiGene
INDUSTRY